Gland Pharma Secures USFDA Approval for Angiotensin II Acetate Injection, Strengthening Critical Care Portfolio

Unknown Apr 02, 2026 1,200 Views

Gland Pharma Ltd. has received final approval from the United States Food and Drug Administration (USFDA) for its Angiotensin II Acetate Injection (2.5 mg/mL Single-Dose Vial), marking a significant milestone in its injectable drug portfolio. The approval grants Gland Pharma first-to-file status,...

Key Highlights

USFDA Approval & Market Entry:

The Angiotensin II Acetate Injection is used to raise blood pressure in adults experiencing septic shock, a critical condition requiring immediate intervention.

Gland Pharma will launch the product with its marketing partner, ensuring widespread availability in U.S. hospitals.

Market Potential & Competitive Edge:

The drug has reported U.S. sales of approximately $38 million for the 12 months ending September 2023, according to IQVIA data.

Gland Pharma’s first-to-file status allows it to exclusively market the generic version for six months, enhancing revenue potential.

Strategic Expansion & Financial Impact:

The approval strengthens Gland Pharma’s presence in the U.S. injectable drug market, reinforcing its commitment to critical care solutions.

The company reported a 5% increase in revenue from the U.S. market, reaching ₹708.2 crore in Q2 FY24, with the U.S. accounting for 54% of total revenue.

Future Outlook & Growth Strategy:

Gland Pharma continues to expand its sterile injectable portfolio, focusing on high-demand critical care medications.

The company aims to leverage its expertise in complex formulations, ensuring sustained growth in regulated markets.

Gland Pharma’s latest USFDA approval reinforces its leadership in injectable pharmaceuticals, ensuring lifesaving treatments reach patients efficiently.

Source: Gland Pharma Official Announcement, The Hindu Business Line, and CNBC TV18.

Stay Ahead – Explore Now! Honda Launches E-Clutch CB750 Hornet and XL750 Transalp in India